Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061930 | 0.93 | CNR2 (0.54) | CNR2HTR2BHTR7KDM4EALDH1A1 | |
| SCHEMBL13011800 | 0.89 | HIF1A (0.49) | CNR2HTR2BHTR7KDM4EALDH1A1 | |
| SCHEMBL13011755 | 0.87 | HPGD (0.57) | CNR2HTR2BHTR7KDM4EALDH1A1 | |
| SCHEMBL2482662 | 0.85 | HTR2B (0.49) | HTR2BHTR7KDM4EALDH1A1HPGD | |
| SCHEMBL13011760 | 0.85 | HTR2B (0.49) | HTR2BHTR7KDM4EALDH1A1HPGD | |
| SCHEMBL13011754 | 0.85 | NPC1 (0.55) | CNR2ALDH1A1HPGDNPC1 | |
| SCHEMBL13011661 | 0.81 | HTR2B (0.43) | CNR2HTR2BHTR7KDM4EPTGER4 | |
| SCHEMBL13011761 | 0.81 | CNR2 (0.50) | CNR2HTR2BHTR7KDM4EPTGER4 | |
| SCHEMBL13011660 | 0.80 | MEN1 (0.47) | CNR2HTR2BHTR7KDM4EPTGER4 | |
| SCHEMBL13011630 | 0.80 | POLB (0.45) | CNR2HTR2BHTR7KDM4EPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | CNR2 681/4885HTR2B 7/4885HTR7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.